Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca business to Alfasigma

Galapagos NV and Alfasigma S.p.A. announced that they have signed a letter of intent contemplating a transfer of the Jyseleca business to Alfasigma, including the European and UK Marketing Authorizations, the commercial, medical and development activities for Jyseleca and approximately 400 positions in 14 European countries. In the contemplated transaction, Galapagos will receive a €50 million upfront, potential milestone payments […]

Common drug can improve hand osteoarthritis symptoms: Study

Relief could be on the way for people with painful hand osteoarthritis after a Monash University and Alfred Health-led study found an affordable existing drug can help. Until now there has been no effective treatment. Published in The Lancet, the paper investigated methotrexate, a low-cost, effective treatment for inflammatory joint conditions such as rheumatoid arthritis and psoriatic arthritis. It has been widely […]

New study reveals the most common form of arthritis, osteoarthritis, affects 15% of the global population over the age of 30

A new study projects nearly 1 billion people will be living with osteoarthritis, the most common form of arthritis, by 2050. Currently, 15% of individuals aged 30 and older experience osteoarthritis. The research, published today in The Lancet Rheumatology, analyzes 30 years of osteoarthritis data (1990–2020) covering more than 200 countries and was led by the Institute for Health Metrics and Evaluation […]

Well-designed digital health platforms can improve the quality of life for people with Parkinson’s disease and their caregivers

There is a need to better deliver information on medical nutrition therapy for patients with Parkinson’s disease (PD). Findings of a new study in the Journal of Nutrition Education and Behavior, published by Elsevier, show digital health serves as an additional health service resource, which increases the healthcare provider’s abilities to collect current visual and objective data, thereby decreasing patient and caregiver burden […]

Galapagos to review future of Jyseleca

Galapagos revealed that it is weighing up all options for its only approved product, the JAK inhibitor Jyseleca. Galapagos has disclosed its financials for the first half 2023 which show that Jyseleca (filgotinib), approved in Europe for rheumatoid arthritis and ulcerative colitis, reached €54.3 million in sales, up by 54% on the like, year-earlier period but below consensus estimates. The […]

Complete Response Letter for AVT 02 biosimilar candidate for Humira – Alvotech

Alvotech announced that the FDA has issued a complete response letter (CRL) for Alvotech’s second Biologics License Application (BLA) for AVT 02, a high-concentration biosimilar candidate for Humira (adalimumab). As the second of two BLAs submitted for AVT 02, this BLA contained data to support approval as a high-concentration biosimilar and additional information to support the interchangeability designation. The CRL […]

MHRA (UK) expands approval for Xeomin to treat focal spasticity of the lower limbs affecting the ankle joint – Merz Therapeutics

The MHRA (UK) has granted approval for a new indication for Merz Therapeutics’ Xeomin (incobotulinumtoxinA) to treat focal spasticity of the lower limbs affecting the ankle joint. The therapy was previously approved in the UK to treat upper limb spasticity. The expanded approval allows the company to provide holistic support to those living with spasticity who need comprehensive treatment. The […]

A commonly used tool is suboptimal in predicting osteoporosis fracture risk in younger post-menopausal women

The commonly used Fracture Risk Assessment Tool (FRAX), which includes self-identified race and ethnicity information, and the Osteoporosis Self-Assessment Tool (OST), which does not, had suboptimal performance in determining major osteoporotic fracture risk across racial/ethnic categories in younger postmenopausal women. But OST was excellent for identifying who had osteoporosis within each racial/ethnic category. BACKGROUND The researchers sought to compare the […]

Patients with rheumatic and musculoskeletal conditions vulnerable to long term opioid use

Patients with rheumatic and musculoskeletal conditions are vulnerable to long term opioid use, with up to 1 in 3 of those with rheumatoid arthritis or fibromyalgia, who take these drugs for the first time, potentially at risk, suggest the findings of a research letter, published online in the Annals of the Rheumatic Diseases. People with rheumatic and musculoskeletal conditions are often […]